Lipid-lowering therapy in patients with renal disease (Q40981407)

25 September 2017

0 references

Lipid-lowering therapy in patients with renal disease (English)

1 reference

25 September 2017

Massy ZA

1

1 reference

25 September 2017

Ma JZ

series ordinal

2

1 reference

25 September 2017

Louis TA

series ordinal

3

1 reference

25 September 2017

Kasiske BL

series ordinal

4

1 reference

25 September 2017

language of work or name

English

0 references

publication date

1 July 1995

1 reference

25 September 2017

1 reference

25 September 2017

48

1 reference

25 September 2017

1

1 reference

25 September 2017

188-198

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.1995.284

25 September 2017

0 references

cites work

Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

A special, supplemented 'vegan' diet for nephrotic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Partial remission of nephrotic syndrome in patient on long-term simvastatin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Treatment of nephrotic hyperlipoproteinemia with gemfibrozil

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effect of probucol on hyperlipidemia in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

n-3 fatty acids reduce proteinuria in patients with chronic glomerular disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Long-Term Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Patients With Nephrotic Proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Treatment of severe nephrotic syndrome with meclofenamate: an uncontrolled pilot study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Treatment of hypertriglyceridaemia after renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Lipid Disorders in Renal Transplant Recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

The effect of the American Heart Association step one diet on hyperlipidemia following renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Treatment of hyperlipidemic kidney graft recipients with lovastatin: effect on LDL-cholesterol and lipoprotein (a)

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Lovastatin treatment of hypercholesterolemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

The effects of pravastatin on hyperlipidemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Hyperlipidemia after renal transplantation: treatment with gemfibrozil

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Hyperlipidemia in renal transplant recipients: natural history and response to treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Reduction of plasma triglycerides by diet in subjects with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effect of protein-reduced diet on plasma lipids, apolipoproteins and lipolytic activities in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effects of a polyunsaturated fatty acid-rich diet on serum lipids in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Associated Effect of Hepatic Hydroxymethylglutaryl Coenzyme A Reductase + Angiotensin Converting Enzyme Inhibitors on the Progression of Renal Failure in Hypertensive Subjects

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Treatment of uremic hypertriglyceridaemia with bezafibrate

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effects of protein intake variation and omega-3 polyunsaturated fatty acids on renal function in chronic renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effect of a Long-Term Fat-Modified Diet on Serum Lipoprotein Levels of Cholesterol and Triglyceride in Patients on Home Haemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Treatment of hyperlipidaemia in patients on chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Dietary treatment of hyperlipidemia in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Long-term dietary treatment of hyperlipidaemia in patients treated with chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Response of plasma triglycerides to dietary change in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Metabolic effects of exercise training in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effects of self-monitored exercise on selected blood chemistry parameters of end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Carnitine status, plasma lipid profiles, and exercise capacity of dialysis patients: effects of a submaximal exercise program

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Reduced lipid concentrations during four years of dialysis with low molecular weight heparin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effects of erythropoietin therapy on the lipid profile in end-stage renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Blood lipid profile in hemodialysis patients treated with human erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Carnitine improves lipid anomalies in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effects of L-carnitine supplementation in the dialysate on serum lipoprotein composition of hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Plasma lipoproteins, liver function and glucose metabolism in haemodialysis patients: lack of effect of L-carnitine supplementation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Control of clofibrate toxicity in uremic hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Chronic clofibrate therapy in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Increase in Lipoprotein Lipase during Clofibrate Treatment of Hypertriglyceridemia in Patients on Hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Fish oil modifies lipids and reduces platelet aggregability in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effect of vitamin E supplementation on serum and high-density lipoprotein-cholesterol in renal patients on maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Treatment of hyperlipemia in diabetic patients on dialysis with a physiological substance

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Carnitine deficiency induced during hemodialysis and hyperlipidemia: effect of replacement therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Favorable effects of L-carnitine treatment on hypertriglyceridemia in hemodialysis patients: decisive role of low levels of high-density lipoprotein-cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Response patterns to DL-carnitine in patients on maintenance haemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Plasma carnitine concentrations and dyslipidemia in children on maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Serum free carnitine, carnitine esters and lipids in patients on peritoneal dialysis and hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Carnitine depletion as a probable cause of hyperlipidemia in uremic patients on maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effect of lovastatin on serum lipid profile in the treatment of dyslipoproteinaemia in uraemic patients on continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Effects of dietary fish oil on serum lipids and blood coagulation in peritoneal dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Hyperlipidemia in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Lipoprotein metabolism and renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Management of hyperlipidemia of kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

1 reference

https://api.crossref.org/works/10.1038%2FKI.1995.284

7 January 2021

Identifiers

DOI

10.1038/KI.1995.284

1 reference

Dimensions Publication ID

25 September 2017

0 references

1 reference